BLAINJECTIONINJECTABLE
Approved
Sep 2021
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
3/8 — Basic
BYOOVIZ (ranibizumab-nuna) by Samsung Bioepis is vascular endothelial growth factor inhibitors [moa]. First approved in 2021.
Drug data last refreshed 26m ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BYOOVIZ is a monoclonal antibody (mAb) biosimilar of ranibizumab developed by Samsung Bioepis, approved in 2021. It is a VEGF inhibitor designed to treat retinal conditions characterized by abnormal blood vessel growth. The drug works by binding vascular endothelial growth factor to prevent neovascularization and reduce vision loss.
Peak
Product is at peak commercialization with moderate competitive pressure (30/100), suggesting stable team size and resource allocation within the Samsung Bioepis ophthalmology portfolio.
Mechanism of Action
Vascular Endothelial Growth Factor Inhibitors
Pharmacologic Class:
Vascular Endothelial Growth Factor Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on BYOOVIZ offers career exposure to biosimilar commercialization strategy, payer negotiation, and ophthalmology market dynamics in a mature, competitive space. The role emphasizes market access, formulary positioning, and cost-of-therapy arguments rather than novel clinical development or launch-phase excitement.
Brand Manager
Worked on BYOOVIZ at Samsung Bioepis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.